Compare · CATB vs FLXN
CATB vs FLXN
Side-by-side comparison of Catabasis Pharmaceuticals, Inc. (CATB) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CATB and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN is the larger of the two at $458.9M, about 3.8x CATB ($121.4M).
- FLXN has more recent analyst coverage (7 ratings vs 2 for CATB).
- Company
- Catabasis Pharmaceuticals, Inc.
- Flexion Therapeutics, Inc.
- Price
- $8.57-7.15%
- $25.11-0.20%
- Market cap
- $121.4M
- $458.9M
- 1M return
- -
- -0.20%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 7
Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest CATB
- SEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- SEC Form 4 filed by Violin Jonathan
- SEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
- Wedbush initiated coverage on Catabasis Pharmaceuticals with a new price target
- Catabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-8 filed by Catabasis Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)